Faeth Therapeutics, Inc. - Asset Resilience Ratio
Faeth Therapeutics, Inc. (FTH) has an Asset Resilience Ratio of 84.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see Faeth Therapeutics, Inc. balance sheet assets.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Faeth Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read FTH total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Faeth Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See Faeth Therapeutics, Inc. (FTH) liquidity interval to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $159.54 Million | 84.28% |
| Total Liquid Assets | $159.54 Million | 84.28% |
Asset Resilience Insights
- Very High Liquidity: Faeth Therapeutics, Inc. maintains exceptional liquid asset reserves at 84.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Faeth Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Faeth Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX |
Biotechnology | 0.00% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 10.17% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Faeth Therapeutics, Inc. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Faeth Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 54.65% | $12.52 Million | $22.90 Million | -14.44pp |
| 2024-12-31 | 69.09% | $31.34 Million | $45.36 Million | -1.83pp |
| 2023-12-31 | 70.92% | $52.75 Million | $74.37 Million | -4.54pp |
| 2022-12-31 | 75.46% | $89.32 Million | $118.38 Million | -16.21pp |
| 2021-12-31 | 91.67% | $140.46 Million | $153.22 Million | -- |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more